Benign multiple sclerosis and long-term outcomes after 30 years
Journal of Neurology · 2025
DOI: 10.1007/s00415-025-13402-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurology, 2025. Verfasst von E Matas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Feixa Llarga s/n, 08907, Barcelona, …. Hauptthemen laut MEDLINE: Multiple Sclerosis, Disease Progression. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundació Institució dels Centres de Recerca de Catalunya.
Abstract (Originalsprache)
Background
The concept of benign multiple sclerosis (MS) is a matter of debate. In most definitions, only the Expanded Disability Status Scale (EDSS) score and disease duration are considered, although other factors may influence a patient’s disability. The aims of this study were to evaluate the percentage of patients with benign MS in our cohort and to determine the proportion of these patients who remained benign after 20 and 30 years of disease evolution. Clinical and demographic variables related to this outcome were investigated.
Methods
Patients fulfilling the criteria for benign MS (EDSS < 3.0 and at least 10 years of MS evolution) were selected from a hospital-based series and followed up prospectively. The EDSS was assessed after 20 and 30 years of MS evolution. Clinical and radiological variables were evaluated. Fatigue, depression and cognition tests were performed.
Results
Eighty-two of the 485 patients evaluated in 1996 fulfilled the criteria for benign MS and were selected. In 51 of the 68 (75%) patients evaluated in 2006, the EDSS score continued to be ≤ 3. In 2016, 35 out of 58 (60%) patients continued to have an EDSS score ≤ 3. None of the clinical variables could predict persistence in the benign group. Eighteen of the 35 benign MS patients completed the questionnaires after 30 years. Fifty percent of them reported fatigue, 22% depression, and 83% had cognitive impairment.
Conclusion
The majority of MS patients maintained a benign status even after 30 years of disease evolution. However, cognitive impairment in this group is notable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Feixa Llarga s/n, 08907, Barcelona, Spain. ematas@bellvitgehospital.cat.
- Neurologic Diseases and Neurogenetics Group, Neuroscience Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. ematas@bellvitgehospital.cat.
- Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Feixa Llarga s/n, 08907, Barcelona, Spain.
- Neurologic Diseases and Neurogenetics Group, Neuroscience Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
- Departament de Ciències Clíniques, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
Förderung
- Fundació Institució dels Centres de Recerca de Catalunya
Zitieren
APA
Matas, E., Bau, L., Romero-Pinel, L., León, I., Arroyo-Pereiro, P., Muñoz-Vendrell, A., Martínez-Yélamos, A., & Martínez-Yélamos, S. (2025). Benign multiple sclerosis and long-term outcomes after 30 years. Journal of Neurology. https://doi.org/10.1007/s00415-025-13402-8
Vancouver
Matas E, Bau L, Romero-Pinel L, León I, Arroyo-Pereiro P, Muñoz-Vendrell A, et al. Benign multiple sclerosis and long-term outcomes after 30 years. Journal of Neurology. 2025. doi:10.1007/s00415-025-13402-8
BibTeX
@article{Matas2025,
author = {Matas, E and Bau, L and Romero-Pinel, L and León, I and Arroyo-Pereiro, P and Muñoz-Vendrell, A and Martínez-Yélamos, A and Martínez-Yélamos, S},
title = {Benign multiple sclerosis and long-term outcomes after 30 years},
journal = {Journal of Neurology},
year = {2025},
doi = {10.1007/s00415-025-13402-8}
}
EUVIMED